%20(2).png){kind=logo}
Fierce Pharma features Ostro’s analysis on why 65% of HCP digital interactions lead nowhere—and how AI-powered journey orchestration can change that.
Digital health leaders welcomed Trump’s AI Action Plan for promoting innovation through deregulation and data standards but flagged gaps in AI safety, patient consent, and regulatory oversight.
Industry leaders are bracing for Trump’s new reciprocal tariffs and the threat of steep biopharma duties that could disrupt global drug trade despite WTO rules.
Ostro is a 2025 Fierce Pharma Marketing Awards finalist in the "New Brand Launch" category for its work on the Ostro x BridgeBio Attruby launch.
Ostro CEO Chase Feiger explains how regulatory compliance can serve as a strategic enabler, fostering trust and accelerating AI innovation in pharmaceutical development.
Big Pharma is adopting marketing tactics from pro athletes—such as personal branding, storytelling, and influencer-style engagement—to build trust and connect more authentically with patients.
Trump’s proposed megabill includes provisions that could boost the biotech industry, particularly by streamlining FDA approvals and expanding support for domestic biomanufacturing.
GLP-1 drugs like Ozempic are reshaping consumer behavior beyond food by disrupting industries such as retail, casinos, airlines, and fitness, prompting brands to rethink engagement strategies.
Fierce Pharma Week unites top life science leaders in marketing, sales, medical affairs, PR & Communications, and commercialization to ignite innovation and drive strategy. Get ready to accelerate your brand's impact, power agile growth, and thrive in pharma’s fast-paced future.
.svg)